Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment
21 juil. 2021 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned...
Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021
17 juil. 2021 19h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, July 17, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
16 juil. 2021 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, July 16, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
21 juin 2021 09h15 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
19 juin 2021 18h30 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
REPEAT - Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
14 juin 2021 09h15 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its...
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
12 juin 2021 18h39 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 12, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its...
REPEAT – Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
06 mai 2021 09h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
06 mai 2021 03h10 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
REPEAT - World Renowned Physician Joins Core One Labs as Chief Medical Officer
05 mai 2021 09h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has...